The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 500 links to online copies of actual pharmacogenomic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of pharmacogenomic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pharmacogenomic dealmaking since 2005, including details of average headline, upfront, milestone and royalty terms.
Published: February 2012
No. of Pages:538
Price: Single User License: US$ 2695 Corporate User License: US$ 13475
Pharmacogenomic Partnering Terms and Agreements includes:
Pharmacogenomic Partnering Terms and Agreements provides the reader with the following key benefits:
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 500 links to online copies of actual pharmacogenomic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of pharmacogenomic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pharmacogenomic dealmaking since 2005, including details of average headline, upfront, milestone and royalty terms.
Pharmacogenomic Partnering Terms and Agreements Market
Published: February 2012
No. of Pages:538
Price: Single User License: US$ 2695 Corporate User License: US$ 13475
Pharmacogenomic Partnering Terms and Agreements includes:
- Trends in pharmacogenomic dealmaking in the biopharma industry since 2007
- Analysis of pharmacogenomic deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life pharmacogenomic deals
- Access to over 500 pharmacogenomic contract documents
- The leading pharmacogenomic deals by value since 2007
- Most active pharmacogenomic dealmakers since 2007
- The leading pharmacogenomic partnering resources
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Pharmacogenomic Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of pharmacogenomic deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of pharmacogenomic agreements with numerous real life case studies
- Comprehensive access to over 500 actual pharmacogenomic contracts entered into by the world’s biopharma companies
- Detailed access to actual pharmacogenomic contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a pharmacogenomic agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
